Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Koenig – page 126

1 643 clinical trials in Bad Koenig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Koenig at a glance
1 643
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 643 trials in Bad Koenig

Open in trial search

Study of CGT9486 and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bezuclastinib
  • Sponsor:Cogent Biosciences Inc.

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Study on Botensilimab and Balstilimab for Patients with Advanced Melanoma Resistant to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Agenus Inc.

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Renal cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Hepatitis D

Not recruiting

Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Gilead Sciences Inc.

Study on the Safety and Effectiveness of MK-5475 for Adults with Pulmonary Hypertension and COPD

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Frespaciguat
  • Sponsor:Merck Sharp & Dohme LLC

Study of LY3819469 for Adults with High Lipoprotein(a) Levels

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3819469 sodium
  • Sponsor:Eli Lilly & Co.

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of DKN-01 with Drug Combination for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Leap Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Koenig

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease. These studies are investigating innovative approaches for patients undergoing regular dialysis treatment.

  • Cardiovascular Outcomes
  • Inflammatory Biomarkers
  • Dialysis Patient Care

Current research aims to evaluate new therapeutic interventions targeting C-reactive protein levels, a key marker of inflammation in cardiovascular disease, potentially offering new hope for dialysis patients dealing with cardiovascular complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.